Skip to content
Disclosery

TRV GP IV, LLC

Follow

13F filer, CIK 1688325, Boston, MA

TRV GP IV, LLC reported $255,124,806 across 2 holdings for the quarter ended 2025-12-31, in a 13F-HR filed 2026-02-13.

Filed (acceptance time not in the bulk data set), ingested 13F-HR 0001193125-26-051795

Period
2025-12-31
Reported value
$255M
Holdings
2
Top 10 weight
100%
New
0
Sold out
0

Largest buys vs the previous quarter

None.

Largest sells vs the previous quarter

SecurityShares changeApprox. value
MAZEreduced-1,600,000-$66.3M
TNGXreduced-5,989,401-$53.1M

Ranked by the share change valued at this quarter's implied price (value over shares in the 13F). A position sold out is valued at the previous quarter's price, its last report.

Holdings, Q4 2025

Share positions as resolved from 13F-HR 0001193125-26-051795, largest first. % of portfolio is the value over $255,124,806, the sum of the share positions whose value is usable for ratios (method).

SecurityHistorySharesValue% of portfolioChangeLatest eventTimeline
MAZEMAZE THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: not reported; 2024Q4: not reported; 2025Q1: 6,073,958 shares; 2025Q2: 6,073,958 shares; 2025Q3: 6,073,958 shares; 2025Q4: 4,473,958 shares 4,473,958$185M72.65%-1,600,000Timeline
TNGXTANGO THERAPEUTICS INCQuarterly shares; oldest to newest; scale is this security's eight-quarter maximum; 2024Q1: restricted; 2024Q2: restricted; 2024Q3: 16,859,075 shares; 2024Q4: 16,859,075 shares; 2025Q1: 16,859,075 shares; 2025Q2: 16,859,075 shares; 2025Q3: 13,863,975 shares; 2025Q4: 7,874,574 shares 7,874,574$69.8M27.35%-5,989,401Timeline

How Q4 2025 was built

Available 13F filings of this filer for the quarter and their roles: the base report is the latest original or restatement, NEW HOLDINGS amendments filed after it are added (method).

FilingRoleAmendmentFiledAcceptedIngested
13F-HR 0001193125-26-051795 base2026-02-13acceptance time not in the bulk data set